Department of Neurology, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, 500 Hofstra Blvd, Hempstead, New York, USA; Department of Neurology, North Shore University Hospital, Manhasset, NY, USA.
Department of Neurology, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, 500 Hofstra Blvd, Hempstead, New York, USA; Department of Neurology, North Shore University Hospital, Manhasset, NY, USA; Department of Neurology, Lenox Hill Hospital, New York, NY, USA.
Mult Scler Relat Disord. 2020 Sep;44:102341. doi: 10.1016/j.msard.2020.102341. Epub 2020 Jun 26.
It is unknown whether MS disease modifying therapies impact ability to mount an antibody response to SARS-CoV-2.
Case series and literature review. We report a series of two MS patients who developed COVID-19 while on Ocrelizumab therapy and subsequently exhibited negative SARS-CoV-2 serology.
A 42-year-old man and 39-year-old woman with MS developed COVID-19 while on Ocrelizumab therapy. Neither patient required hospitalization. The man exhibited negative serology at 7- and 9-weeks post-infection. The woman exhibited negative serology at 6- and 12-weeks post-infection.
Large studies are essential to determine whether certain DMTs may blunt SARS-CoV-2 antibody production.
目前尚不清楚多发性硬化症的疾病修正治疗是否会影响机体对 SARS-CoV-2 产生抗体的能力。
病例系列和文献回顾。我们报告了两例多发性硬化症患者在接受奥瑞珠单抗治疗时发生 COVID-19，随后 SARS-CoV-2 血清学检测结果为阴性。
一名 42 岁男性和一名 39 岁女性在接受奥瑞珠单抗治疗时发生 COVID-19。两名患者均无需住院治疗。该男性在感染后 7 周和 9 周时血清学检测结果为阴性。该女性在感染后 6 周和 12 周时血清学检测结果为阴性。
需要开展大型研究来确定某些 DMT 是否可能削弱 SARS-CoV-2 抗体的产生。
